Skip to main content

Subtle Medical

Category: AI in Healthcare

AI-powered vendor-neutral medical imaging software that enables faster, safer, and higher-quality MRI and PET scans through deep learning. Subtle Medical was founded in 2017. The company is led by Ohad Arazi (appointed June 2026); Enhao Gong, PhD (co-founder, transitioned to Chief Science Officer). Based in Menlo Park, California. Team size: 101-500. Total funding raised: $86M. Latest round: Series C. Key investors include Morgan Stanley Expansion Capital, Shinhan Venture Investment, Fusion Fund, EnvisionX Capital, BRV Capital, Samsung Ventures, Ignite Innovation, 3E Bioventures Capital, Bessemer Venture Partners, ZhenFund (Momentor Ventures), Data Collective (DCVC), Breyer Capital.

Founded
2017
Headquarters
Menlo Park, California
Team size
101-500
Total funding
$86M

Value proposition

Subtle Medical provides AI-powered, vendor-neutral software that overlays existing MRI, PET, and CT scanners to dramatically accelerate scan times (up to 80% faster), improve image quality, reduce radiation/contrast dosage, and increase scanner throughput by 4-5 additional patient slots per day — without requiring new hardware purchases.

Products and solutions

Subtle-ELITE™ Package (includes SubtleHD™(MR), SubtleSYNTH™, SubtleALIGN™), SubtleHD™(PET), AiMIFY™ (sold by Bracco), SubtleGAD™ (in progress), SubtleIR™ (fluoroscopy AI, in development), Imaging Hub (unified enterprise AI platform across modalities)

Unique value

Vendor-neutral AI imaging layer that works across all major scanner manufacturers (Siemens, GE, Philips, etc.), addressing the image acquisition stage rather than the crowded downstream diagnostics market — enabling 80% faster scans, 50%+ higher throughput, and proven ROI without capital equipment upgrades.

Target customer

Hospitals, health systems, imaging centers, radiology networks, academic medical centers, and OEM medical imaging manufacturers

Industries served

Healthcare / Medical Imaging / Radiology

Technology advantage

Deep learning and generative AI models for medical image denoising, sharpening, synthetic contrast generation, and automated alignment. 11 FDA clearances, 30+ issued/pending patents, 25+ peer-reviewed publications. Exclusive licensing rights to Stanford University technology (2016). First-to-market FDA-approved AI for MRI and PET image acquisition enhancement.

How they differentiate

Unlike most radiology AI companies that focus on diagnostic interpretation (reading/analyzing images), Subtle Medical focuses on the image acquisition stage — improving how images are captured. This is vendor-neutral (works across all scanner OEMs), multi-modality (MRI, PET, CT), and delivers throughput gains of 4-5 additional patient slots per scanner per day, providing clear ROI for health systems.

Main competitors

Aidoc, Viz.ai, Lunit, Qure.ai, Annalise.ai, Cleerly, Zebra Medical Vision (Nanox), Brainomix

Key partnerships

Siemens Healthineers (OEM partnership), Bracco (AiMIFY™ co-marketing), Bayer (pharmaceutical partnership), GE Healthcare, Philips (China), NVIDIA (NVIDIA Inception AI award recipient), National Institutes of Health (NIH SBIR grants)

Notable customers

Mount Sinai Health System, RadNet, Radiology Partners, SimonMed Imaging, Rezolut

Major milestones

2017: Founded at Stanford University, 2018: First FDA clearance for SubtleMR, 2019: First FDA clearance for SubtlePET, 2020: $12.2M Series A, 2022: $25M Series B, 2023: $2.3M NIH SBIR grant for SubtleSYNTH™, 2024: Series B+ with Samsung Ventures, total Series B >$30M, 2025: TIME World's Top HealthTech Companies, 2.5x revenue growth, 2026: $33M Series C led by Morgan Stanley, Ohad Arazi appointed CEO, 11 FDA clearances total

Growth metrics

2.5x annualized revenue growth in US (2025); deployed on 1,300+ scanners globally; 600+ US installations; 2.5M+ patients served annually; 2x YoY growth sustained through 2024

Market positioning

Market leader in AI-powered medical image acquisition. Named to TIME World's Top HealthTech Companies 2025, multiple-time CB Insights Top AI 100, Digital Health 150, and GenAI 50. Deployed on 1,300+ scanners globally across major imaging networks.

Geographic focus

Global: US (primary), Europe (UK, EU), Latin America, APAC (China, Southeast Asia, entering Korea and Japan in 2024)

Patents and IP

30+ issued and/or pending patents globally; exclusive licensing rights to technology developed at Stanford University in 2016

About Ohad Arazi (appointed June 2026); Enhao Gong, PhD (co-founder, transitioned to Chief Science Officer)

Ohad Arazi: Former CEO of Clarius Mobile Health (AI-powered ultrasound); former CEO of Zebra Medical Vision; leadership roles at Genoox, TELUS Health, and McKesson/Change Healthcare's PACS business. Enhao Gong, PhD: PhD in Electrical Engineering from Stanford University; Forbes 30 Under 30; deep learning scientist specializing in medical imaging AI.

Official website: